| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:459.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
From the Hypertension and Cardiovascular Rehabilitation Unit (R.H.F., J.A.S., L.T., H.C.), University of Leuven, Leuven, Belgium; Erasmus University (W.H.B.), Rotterdam, the Netherlands; Imperial College, Hammersmith Hospital (C.J.B.), London, UK; University of Maastricht (P.W.d.L.), Maastricht, the Netherlands; Istituto Auxologico Italiano (G.L.), Ospedale San Luca, Milano, Italy; National Public Health Institute and the University of Helsinki (C.S., J.T.), Helsinki, Finland; Clinical Pharmacology Unit (J.W.), Aberdeen Royal Infirmary, Aberdeen, UK; Department of Family Medicine (Y.Y.), Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel.
Correspondence to R. Fagard, MD, PhD, Professor of Medicine, Hypertension and Cardiovascular Rehabilitation Unit, U.Z.Gasthuisberg-Hypertensie, Herestraat 49, B-3000 Leuven, Belgium. E-mail robert.fagard{at}uz.kuleuven.ac.be
The aim of the present study was to assess the prognostic value of ECG voltages at baseline and their serial changes during follow-up in a large prospective study with standardized follow-up and strictly defined end points. Patients who were 60 years old or older, with systolic blood pressure of 160 to 219 mm Hg and diastolic pressure <95 mm Hg, were randomized into the double-blind placebo-controlled Systolic Hypertension in Europe trial. Active treatment consisted of nitrendipine, which could be combined with or replaced by enalapril, hydrochlorothiazide, or both. At the end of the double-blind part of the trial (median follow-up, 2.0 years), follow-up was extended and all patients received active study drugs (median total follow-up, 6.1 years). Electrocardiography was performed at baseline and yearly thereafter. Electrocardiographic left ventricular mass was prospectively defined as the sum of 3 voltages (RaVL+SV1+RV5), which averaged 3.1±1.0 mV. The adjusted relative hazard rate, associated with a 1 mV higher sum at baseline, amounted to 1.10 and 1.15 for all-cause and cardiovascular mortality and to 1.21 and 1.18 for strokes and cardiac events, respectively (P
0.01 for all). A 1-mV decrease in electrocardiographic voltages during follow-up independently predicted a lower incidence of cardiac events (relative hazard rate: 0.86; P
0.05), but not of stroke or mortality. In conclusion, electrocardiographic voltages at baseline and their serial changes during follow-up predict subsequent events in older patients with systolic hypertension.
Key Words: antihypertensive therapy elderly electrocardiography hypertension, essential hypertrophy, cardiac prognosis
This article has been cited by other articles:
![]() |
P. M. Okin, L. Oikarinen, M. Viitasalo, L. Toivonen, S. E. Kjeldsen, M. S. Nieminen, J. M. Edelman, B. Dahlof, R. B. Devereux, and for the LIFE Study Investigators Prognostic Value of Changes in the Electrocardiographic Strain Pattern During Antihypertensive Treatment: The Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE) Circulation, April 14, 2009; 119(14): 1883 - 1891. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Okin, R. B. Devereux, K. E. Harris, S. Jern, S. E. Kjeldsen, S. Julius, J. M. Edelman, B. Dahlof, and for the LIFE Study Investigators Regression of Electrocardiographic Left Ventricular Hypertrophy Is Associated with Less Hospitalization for Heart Failure in Hypertensive Patients Ann Intern Med, September 4, 2007; 147(5): 311 - 319. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
![]() |
A. Delgado-Almeida, M. P. Schneider, R. E. Schmieder, R. H. Fagard, and on behalf of the Syst-Eur investigators Critical Value of the Electrocardiogram in LVH: From Predictive Index to Therapeutic Reassessment Hypertension, February 1, 2005; 45(2): e6 - e7. [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |